NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
IranStrikesIranianIsraelMilitaryTrumpLeadershipSupremeLeaderKhameneiIsraeliCrisisTargetingRegionalLaunchPowerMarchTimelineDigestSundayFaceSignificantSuccessionSecurity
IranStrikesIranianIsraelMilitaryTrumpLeadershipSupremeLeaderKhameneiIsraeliCrisisTargetingRegionalLaunchPowerMarchTimelineDigestSundayFaceSignificantSuccessionSecurity
All Articles
To Your Good Health : The cost of medicine for IBS is $811 even with insurance
agrinews-pubs.com
Published about 5 hours ago

To Your Good Health : The cost of medicine for IBS is $811 even with insurance

agrinews-pubs.com · Mar 1, 2026 · Collected from GDELT

Summary

Published: 20260301T031500Z

Full Article

After a month of testing from my gastrointestinal doctor, I have been diagnosed with irritable bowel syndrome. I have been sick for several months and have lost 12 pounds. I’m now down to 100 pounds. I have been prescribed Xifaxan. The cost from my pharmacy is $811. Normally, I never have a co-pay. I checked around and there are no discounts with any other pharmacies. I read many chats about the medicine and 50% of people in these chats believe that it does not work well and is very hard to digest for the two weeks that you have to take it. I am meeting with a nutritionist to increase my weight, but every couple of days I get so sick due to the IBS and can’t gain weight. What are your thoughts on taking this medication?IBS is a functional disease of the intestine. The cause is not certain and there are several factors involved in IBS, including abnormal movement of the intestine, changes in pain sensitivity, unhealthy bacteria in the gut; and often sensitivities to certain foods.The hallmarks of IBS are changes in bowel habits — diarrhea, constipation or both — and abdominal pain, which is often but not always improved after a bowel movement.Xifaxan, or rifaximin, is an antibiotic that is not well-absorbed in the body, so it only kills the bacteria in the gut. It is intended to preferentially kill harmful bacteria in the gut, improving the microbiome and decreasing bacterial products that cause symptoms of bloating and diarrhea.I have several patients who take it occasionally when other therapies aren’t working and their experience has been favorable.When used wisely, it can help people with their symptoms. Of course, patients in whom it doesn’t work aren’t going to use it again, but it does work well for some people.The $811 cost with insurance is much better than the $2,500 to $3,200 cost for a course of treatment without insurance.People do not take it for a long time; my patients typically take a course one to four times per year. If it helps you, I hope you find it worth the expense, but I don’t know whether you are fortunate to have this much money to spend on prescriptions that are over and above your insurance costs.Severe weight loss with IBS is not common and should be considered an alarming symptom. I have seen many patients who were diagnosed with IBS, sometimes for years, before another comprehensive evaluation is performed.This sometimes lead to the diagnosis of inflammatory bowel disease — Crohn’s disease or ulcerative colitis.If you have not had a recent evaluation, including an endoscopy and/or a colonoscopy, as well as stool studies, it may be time to repeat these.What are the benefits of washing your hands?Not getting sick is the main one. Regular handwashing reduces respiratory illnesses — colds, flu and pneumonia — by about 20%. Handwashing reduces foodborne gastrointestinal illnesses by about 30%.You also reduce the likelihood of passing on germs to others. People are the most contagious right before symptoms start for most respiratory diseases.Health-care professionals wash their hands, or use hand sanitizer, before and after every patient. It only takes 20 seconds for it to be effective.


Share this story

Read Original at agrinews-pubs.com

Related Articles

Science Daily34 minutes ago
Hidden ingredient in Ozempic and Wegovy tablets raises new gut health questions

Scientists are taking a closer look at the pill forms of Wegovy and Ozempic. In an animal study, the ingredient SNAC, which helps semaglutide survive the stomach and enter the bloodstream, was associated with changes in gut bacteria, inflammation markers, and a brain linked protein. The research does not show harm in people, but it raises new questions about the long term effects of daily exposure.

weny.comabout 4 hours ago
Community Health Expo offers free resources in Corning

Published: 20260301T040000Z

bhaskar.comabout 8 hours ago
Holi 2026 Mawa Adulteration Health Risk Alert ; Real Vs Fake Khoya Purity Test

Published: 20260301T003000Z

NPR Newsabout 13 hours ago
"One year of failure." The Lancet slams RFK Jr.'s first year as health chief

In a scathing review, the top US medical journal's editorial board warned that the "destruction that Kennedy has wrought in 1 in office might take generations to repair."

Al Jazeeraabout 21 hours ago
Kazakhstan’s train hospital brings healthcare to remote regions

101 East joins doctors on board a medical train delivering vital healthcare to Kazakhstan’s most remote communities.

Bloomberg1 day ago
The Key to a Healthy Woman's Heart

February is American Heart Month, known as a critical time for bringing increased attention to cardiovascular health and the prevention of heart disease, which is the leading cause of death in the US. Women are particularly vulnerable to cardiac health threats spanning biological, clinical and healthcare system factors that contribute to underdiagnosis, delayed treatment, and worse outcomes compared to men. Dr. Joy Gelbman, Associate Professor of Medicine at Weill Cornell Medicine as well as a board-certified cardiologist, is well-versed in the unique challenges facing women when it comes to their cardiac health. She breaks down specific sex-specific risk factors, differing disease presentation and pathophysiology, as well as the experience disparities in treatments and outcomes. Dr. Gelbman speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily. (Source: Bloomberg)